GSK goes for expanded COPD label with triple combo

14 February 2018
gsk-building-big

In a fast-moving chronic obstructive pulmonary disease (COPD) field where triple combination therapies are driving much of the momentum, GlaxoSmithKline (LSE: GSK) has sought to widen its patient population in Europe.

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), developed by the UK drugmaker and its partner Innoviva (Nasdaq: INVA), is already approved in Europe as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-adrenergic agonist.

Now the company has submitted data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta, meaning it could be used by physicians to treat a wider population of patients with the condition who are at risk of an exacerbation and require triple therapy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical